AMLXAmylyx Pharmaceuticals, Inc.

Healthcare
$28.14+111% 1Y

Price

+111%1Y

End-of-day closes, not the intraday tick.

RyuScore

Weak, higher than 5% of companies
8/100
Seven criteria, weighted: see how it is built

The five questions

2 of 5 available

Only two of the five can be answered for AMLX today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.

  • Is the business good?not enough filed
  • Is it safe?Mixed
  • Is the price fair?not enough filed
  • Is it growing?not enough filed
  • What is the market doing?Mixed
What they do

Amylyx Pharmaceuticals, Inc. (also referred to as Amylyx, we, our or us) is a clinical-stage pharmaceutical company with a mission to develop and advance novel therapies for communities with high unmet medical needs. We have preclinical and clinical development programs underway in endocrine conditions and neurodegenerative diseases. We are advancing a pipeline in which we have matched investigational therapies with diseases for which we believe these therapies can make the greatest impact, based on well-defined mechanistic rationales, clear clinical outcomes and biomarkers, and rigorous preclinical data, agnostic of modality.

In the company’s own words · 10-K filed Mar 3, 2026 · SEC EDGAR

P/En/a
Market value$1.94B
1 year+111%
5 yearsn/a

Charts

As reported to the SEC, without any scoring.

For the full year FY2025, revenue was $0 (−100% year on year) and net income −$145M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.

What the company said

The company's own words from its current reports to the SEC, newest first

  1. Sep 8, 2026On September 8, 2026, Amylyx Pharmaceuticals, Inc. (the “Company”) entered into a Manufacturing and Supply Agreement (the “Bachem Manufacturing Agreement”) with Bachem Americas, Inc. (“Bachem”) and on September 1, 2026, the Company entered into a term sheet (the “Polypeptide Term Sheet”) with Polypeptide Group AG …Material agreement entered · Form 8-K
  2. Aug 20, 2026On August 19, 2026, Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, Morgan Stanley & Co. LLC, Guggenheim Securities, LLC, and LifeSci Capital LLC, as representatives of the several underwriters named therein (the …Material agreement entered · Form 8-K
  3. Aug 18, 2026On August 18, 2026, Amylyx Pharmaceuticals, Inc. (the “Company”) hosted a conference call with investors and analysts to discuss positive topline results from the LUCIDITY Phase 3 clinical trial evaluating the efficacy and safety of avexitide in participants with post-bariatric hypoglycemia following Roux-en-Y gastric …Other event · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.

On our screens:Most shorted stocks

Drug Manufacturers, Specialty & Generic

Ranks #39 of 41 by RyuScore

Compare peers
BHC+0.08%
Bausch Health Companies Inc.
ANIP+2.6%
ANI Pharmaceuticals, Inc.
HCM+2.5%
HUTCHMED (China) Limited
PBH+0.77%
Prestige Consumer Healthcare Inc.
HROW-3.8%
Harrow, Inc.
ETON+0.75%
Eton Pharmaceuticals, Inc.